Generalized hyperpigmentation (GHPT) of the skin may occur as a primary defect of pigmentation or in combination with other variable manifestations. It is visible in a number of diseases such as Addison's disease (AD), haemochromatosis, porphyria cutanea tarda, scleroderma and neurofibromatosis, but it can also be associated with malignancy and the use of chemotherapeutics or it can be related to acanthosis nigricans in insulin resistance. Skin pigmentation depends on the differences in the amount, type and distribution of melanin produced during melanogenesis in skin melanocytes [1] and remains under the genetic control of more than 120 genes [2]. The most important one is the melanocortin 1 receptor (MC1R) gene [3] (OMIM ID: 155555) located on chromosome 16q24.3 and encoding for a 317-amino-acid G-protein coupled receptor. The MC1R receptor binds α-melanocyte-stimulating hormone (α-MSH) resulting in the activation of adenylyl cyclase, which produces cyclic adenosine monophosphate (cAMP). The increased cAMP concentration activates various intracellular molecular pathways, promotes melanin synthesis and increases the eumelanin to pheomelanin ratio [4]. MC1R receptor also binds ACTH, in this way contributing to the GHPT in AD.

Upregulation of MC1R gene expression by UV radiation and α-MSH leads to enhancement of melanogenesis and melanin synthesis induction. Loss-of-function mutations in the MC1R gene are associated with fair skin, poor tanning, propensity to freckles and increased skin cancer risk due to a decrease in eumelanin synthesis and subsequently impaired protection against UV radiation [5-7]. To our knowledge, to date, no data are available considering gain-of-function mutations in the human MC1R gene which could lead to a constant activation of the MC1R receptor and subsequently cause GHPT.

We present the case of a patient with a primary type of progressive GHPT in whom AD was suspected.

An 11-year-old prepubertal girl with GHPT (Figures 1A-C) was born at term with normal birth weight and height and was first brought to our hospital at the age of 3 years with a suspicion of AD. She had a diffuse grey-brownish discoloration of the skin present since birth. Over the first few years of life she developed symmetrical hyperpigmentation most pronounced on her trunk and neck. Later, hyperpigmentation began to affect her hands and feet, and finally the whole body – sparing only the cheeks and finger tips. Her skin was very dry and atopic, and scars were not hyper-
pigmented. Her toenails as well as fingernails had no major alterations. The girl also experienced chronic diarrhoea, once a month on average, that started at the age of 10-12 months, always considered as allergic diarrhoea. She did not have any history of repeating infections. Her mother also reported a strong ammonia odour of the girl’s urine. The remainder of the physical examination, mental development, abdominal ultrasound and magnetic resonance imaging (MRI) of the head were unremarkable. The girl’s height and weight both are on the 25th percentile and the onset of puberty was noticed (thelarche Tanner 2). Metabolic diseases were ruled out by serum and urine analysis. Ophthalmologic and neurologic examinations showed no abnormalities. Familial pedigree analysis did not show any similar cases in the patient’s family. The adrenocorticotropin (ACTH) stimulation test was performed several times by intravenous injection of synthetic ACTH (Table I). Cortisol levels were normal after ACTH stimulation, thus excluding AD. The patient acquired a chickenpox infection which presented as small white, unpigmented spots on the whole body, but hyperpigmentation was still present, especially on the girl’s neck and trunk. A histopathological examination of a skin biopsy from the buttock revealed a strong pigmentation of the epidermal basal layer and melanin aggregates within melanophages of the stratum papillare. The number of melanocytes within the epidermis was unchanged and melanosis diffusa congenita was diagnosed (OMIM ID: 145250).

Written informed consent was obtained from parents and the study was approved by the local Ethics Committee of Poznan University of Medical Sciences. Blood samples were collected and frozen at –20°C until analysis. All laboratory tests were measured in the Central Laboratory of K. Jonscher’s Clinical Hospital of the University using commercial kits. Luteinizing hormone (LH), follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH), parathyroid hormone (PTH), prolactin, estradiol, free thyroxine (T4) and insulin were assayed.
Adrenal function and MC1R gene analysis in a prepubertal girl with generalized hyperpigmentation: case report

by MEIA, thyroid peroxidase antibody (TPO-Ab), 21-hydroxylase-antibody (21-hydroxylase-Ab), cortisol, aldosterone, dehydroepiandrosterone sulphate (DHEA-S) and C-peptide by RIA, and adrenocorticotropic hormone (ACTH) IRMA methods.

Genomic DNA was isolated from peripheral blood leukocytes using QIAGEN® DNA Blood Mini Kit (QIAGEN). Primer sequences used to amplify the MC1R gene as well as polymerase chain reaction (PCR) conditions are available on request. The samples were subjected to direct sequencing using BigDye Terminator v3.1 cycle sequencing kit (Applied Biosystems) and an ABI Prism 3130XL Genetic Analyzer (Applied Biosystems). We did not find any mutations within the whole MC1R gene.

Table 1 Laboratory tests in blood samples (abnormal values are given in bold). A single measurement of oestradiol was elevated at the age of 3 years but with no breast development. Slightly elevated ACTH level at the age of 8 years was probably a result of the morning stress during blood collection. The remaining results were all normal.

| Laboratory tests                    | Results | Reference range |
|------------------------------------|---------|----------------|
|                                    | Age 3   | Age 5          | Age 6 | Age 7 | Age 8 | Age 9 |
| LH [mIU/ml]                        | 0       |                |       |       |       |       |
| FSH [mIU/ml]                       | 2.1     |                |       |       |       |       |
| Oestradiol [pg/ml]                 | 31.0    |                |       |       |       |       |
| Prolactin [ng/ml]                  | 19.5    |                |       |       |       |       |
| TSH [mIU/ml]                       | 1.6     | 2.5            | 1.85  | 3.734 | 1.415 | 0.470–4.640 |
| FT4 [ng/dl]                        | 1.15    | 1.23           | 1.16  |       | 0.71–1.85 |
| TPO-Ab [U/ml]                      | 2       |                | < 60  | < 1   |       |
| 21-hydroxylase-Ab [U/ml]           | 0.82    |                | < 1   |       |       |
| ACTH (basal) [pg/ml]               |         |                |       |       |       |
| 7 am                               | 21.3    | 29.4           | 31.1  | 63.2  | 41.2  | 10–60 |
| Cortisol (basal and stimulated (ACTH test: 250 µg, i.v.)) [µg/dl] |         |                |       |       |       |
| 7 am (time 0)                      | 17.5    |                | 13.1  | 26.9  |       | 9.4–26.0 |
| 7:30 am (time + 30 min)            | 28.3    |                | 22.5  | 31.3  |       |       |
| 8:00 am (time + 60 min)            | 27.5    |                | 32.9  | 38.5  |       |       |
| 8:30 am (time + 90 min)            | 34.5    |                | 33.1  | 36.9  |       |       |
| 9:00 am (time + 120 min)           | 36.5    |                | 35.6  | 43.4  |       |       |
| Cortisol (basal and stimulated (short ACTH test: 1 µg/1.73 m² i.e. 0.4 µg, i.v.)) [µg/dl] |         |                |       |       |       |
| 7 am (time 0)                      | 14.9    |                | 15.0  |       |       | 9.4–26.0 |
| 7:30 am (time + 30 min)            | 22.9    |                | 23.2  |       |       |       |
| 8:00 am (time + 60 min)            | 21.2    |                | 20.1  |       |       |       |
| Aldosterone [pg/ml]                |         | 36.6           |       |       |       |       |
| PRA [ng/ml]                        | 1.99    |                | 0–7   |       |       |
| DHEA-S [µmol/l]                    | 0.65    |                | 1.02–7.16 |       |       |
| Insulin [µIU/ml]                   | 4.8     |                | 0–15  |       |       |
| C-peptide [pmol/ml]                | 1.39    |                | 0.59–1.56 |       |       |
| Glucose [mg/dl]                    | 79.4    | 99             | 93    | 59–101 |       |       |
| HbA1c [%]                          | 5.2     | 5.3            | < 6.1 |       |       |
| Na⁺ [mmol/l]                       | 139     | 134            | 140   | 144   | 139   | 132–145 |
| K⁺ [mmol/l]                        | 4.59    | 4.44           | 4.3   | 4.1   | 3.79  | 3.1–5.1 |
| Mg [mg/l]                          | 21.3    |                | 18.2–23.1 |       |       |
| Ca [mmol/l]                        | 2.60    |                | 2.1–2.6 |       |       |
| P [mg/dl]                          | 4.34    |                | 4.50–5.52 |       |       |
| PTH [pg/ml]                        | 26      |                | 15–65 |       |       |
| EmA-IgA [RU/ml]                    | neg.    |                |       | < 20  |       |
| EmA-IgG                            | neg.    |                | Neg/Pos. |       |       |

Table 1 Laboratory tests in blood samples (abnormal values are given in bold). A single measurement of oestradiol was elevated at the age of 3 years but with no breast development. Slightly elevated ACTH level at the age of 8 years was probably a result of the morning stress during blood collection. The remaining results were all normal.
The most likely diagnosis of the patient with GHPT is primary adrenal insufficiency, subsequent ACTH excess and overstimulation of MC1R in the skin. Recurrent episodes of diarrhoea in the patient could suggest an adrenal crisis but several adrenal function tests, also performed during such episodes, excluded adrenal failure.

Although we did not find any mutations in the coding region of the MC1R gene, or in the untranslated regions or the promoter region, it is possible that disorders in other genes are responsible for the skin pigmentation phenotype in our patient. Branicki et al. showed that HERC2 rs12913832 may be one of the genes responsible for masking the effect of MC1R polymorphisms and significantly affect the function of the MC1R receptor [8]. The phenotype of our patient was characterized by diffuse GHPT, which varied slightly in intensity in different parts of her body. Café-au-lait macules or larger hypopigmented macules were not present. This is contrary to patients previously described in the literature [9]. Therefore, we concluded that the pathogenesis is restricted only to melanogenesis-related functions in the skin.

Familial progressive hyperpigmentation (FPH, OMIM ID: 145250) is a rare congenital diffuse hyperpigmentation disorder affecting the human skin. Familial progressive hyperpigmentation is inherited in an autosomally dominant [9] or recessive [10] manner and is characterized by patches of hyperpigmentation present at birth or in early infancy that increase in size and also in number with age. Ultimately, a large percentage of the skin becomes hyperpigmented. These skin changes always occur on the face, neck, trunk, limbs, lips, oral mucosa and on the palms and soles, but this is not the case for our patient, whose lips, oral mucosa and conjunctiva were not hyperpigmented. Histological examination reveals an increase in the amount of melanin pigment found throughout the epidermis, specifically within the stratum corneum. The skin is the only affected organ and patients do not normally suffer from any other systemic disease [11, 12]. The molecular background of the disease still remains unknown. Zhang et al. examined a three-generation Chinese family consisting of 17 individuals, 6 of whom were affected, including 3 males and 3 females. Contrary to the previous study and our patient, the first onset of the disease in this family was at the age of 5 years, not at birth. All 6 affected members had typical clinical manifestations of FPH. They had normal mental abilities and no systemic disease such as gastrointestinal, liver or kidney ailments. The pedigree of the family showed an autosomal dominant pattern of FPH inheritance [13]. This study gives new potential insight into the plausible bipotential role of ACTH in both adrenal stimulation via MC2R and in skin pigmentation via MC1R, both transduction processes effectively activated at different plasma concentrations of ACTH.

Because there were no disease-causing gain-of-function mutations in the MC1R gene, we concluded that this gene is not responsible for the hyperpigmented phenotype in our patient. Further studies of other candidate genes crucial for human skin pigmentation as well as genetic analysis of the selected SNP polymorphisms will help us to understand the molecular background of the GHPT disorder present in our case.

Acknowledgments

This work was funded by the Department of Paediatric Endocrinology and Rheumatology, Poznan University of Medical Sciences (502-01-0110418-06037).

References

1. Frudakis T. Molecular photofitting. Predicting ancestry and phenotype using DNA. Academic Press 2008.
2. Bennet DC, Lamoreux ML. The color loci of mice – a genetic century. Pigment Cell Res 2003; 16: 333-44.
3. Rees JL. The genetics of sun sensitivity in humans. Am J Hum Genet 2004; 75: 739-751.
4. Sturm RA, Box NF, Ramsay M. Human pigmentation genetics: the difference is only skin deep. Bioassays 1998; 20: 712-21.
5. Box NF, Wyeth JR, O’Gorman LE, Martin NG, Sturm RA. Characterization of melanocyte stimulating hormone receptor variant alleles in twins with red hair. Hum Mol Genet 1997; 6: 1891-7.
6. Smith R, Healy E, Siddiqui S, et al. Melanocortin 1 receptor variants in an Irish population. J Invest Dermatol 1998; 111: 119-22.
7. Bastiaens M, ter Huurne J, Gruis N, et al. The melanocortin-1 receptor gene is the major freckle gene. Hum Mol Genet 2001; 10: 1701-8.
8. Branicki W, Brudnik U, Wojas-Pelc A. Interactions between HERC2, OCA2 and MC1R may influence human pigmentation phenotype. Ann Hum Genet 2009; 73: 160-70.
9. Zanardo L, Stolz Z, Schmitz G, et al. Progressive hyperpigmentation and generalized lentiginosis without associated systemic symptoms: a rare hereditary pigmentation disorder in South-East Germany. Acta Derm Venereol 2004; 84: 57-60.
10. Hüffmeier U, Hausser I, Reis A, Rauchi A. Novel autosomal recessive progressive hyperpigmentation syndrome. Am J Med Genet 2005; 135A: 195-9.
11. Rebora A, Parodi A. Universal inherited melano dyschromatosis: a case of melanosis universalis hereditaria? Arch Dermatol 1989; 125: 1442-3.
12. Debao L, Ting L. Familial progressive hyperpigmentation: a family study in China. Brit J Derm 1991; 125: 607.
13. Zhang C, Deng Y, Chen X, et al. Linkage of a locus determining familial progressive hyperpigmentation (FPH) to chromosome 19p13.1-pter in a Chinese family. Eur J Dermatol 2006; 16: 246-50.